Dr. Riess on the Long-Term Benefit With Immunotherapy for Lung Cancer

Video

Jonathan Riess, MD, assistant professor of medicine, Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses the long-term benefit with immunotherapy for patients with lung cancer.

Jonathan Riess, MD, assistant professor of medicine, Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses the long-term benefit with immunotherapy for patients with lung cancer.

According to Riess, patients with stage IV non

Related Videos
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Elias Jabbour, MD
Shruti Tiwari, MD
Jeffrey P. Townsend, PhD
Marina Baretti, MD
George R. Simon, MD, FACP, FCCP
Related Content
Mansoor Raza Mirza, MD, chief oncologist, Rigshospitalet — Copenhagen University Hospital

Dostarlimab/Chemo Receives FDA Priority Review for Expanded Indication in Endometrial Cancer

April 24th 2024
Article
Hari B. Keshava, MD

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

October 23rd 2023
Podcast
Mark Lanasa, MD, PhD

Tislelizumab Receives EU Approval in 3 Indications for First- and Second-Line NSCLC

April 23rd 2024
Article
Adnan F. Danish, MD

Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers

August 7th 2023
Podcast
Bradley J. Monk, MD, FACS, FACOG, Florida Cancer Specialists & Research Institute

FAK Inhibition Emerges as a Potential Complementary Treatment Pathway

April 22nd 2024
Article
FDA

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC

April 18th 2024
Article